RxDoctor Payments Data

Mary Hitt

Family · Springfield, ILNPI 1528393097

Payments from drug & device makers

$2,871in general payments, 2019–2025

Across 46 payments — averaging $62.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Convatec Inc.$293
  • Astellas Pharma US Inc$238
  • Coloplast$225
  • 180 Medical, Inc.$155
  • Sumitomo Pharma America, Inc.$136
  • plus $121 from 2 others

What the payments were for

  • Travel & lodging$1,18341%
  • Food & beverage$1,48152%
  • Education$2077%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic16$1,703
Convatec Inc.7$293
Astellas Pharma US Inc5$238
Coloplast7$225
180 Medical, Inc.6$155
Sumitomo Pharma America, Inc.2$136
Amgen2$115
Boston Scientific1$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,871 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$36,724
Medicare patients
112
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron124$78,841
GemtesaVibegron57$56,609
EstringEstradiol21$10,895
Estradiol115$7,533
Estradiol (Once Weekly)Estradiol49$2,085
YuvafemEstradiol11$1,784
Solifenacin Succinate38$1,499
Clobetasol Propionate13$1,176
ProgesteroneProgesterone, Micronized31$901
Fesoterodine Fumarate ErFesoterodine Fumarate14$890
Oxybutynin Chloride ErOxybutynin Chloride17$837
Cephalexin18$499
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$238$78,841124 claims
Sumitomo Pharma America, Inc.Gemtesa$136$56,60957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.

Other family in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →